5113.5000 -13.00 (-0.25%)
NSE May 14, 2025 14:59 PM
Volume: 92,450
 

5113.50
-0.25%
Motilal Oswal
With an established presence in the Domestic Formulation (DF) segment and exports, ALKEM is boosting its growth prospects in the bio-CDMO and med-tech segments. The overall investment in the bio-CDMO segment is expected to be ~INR14b.
Alkem Laboratories Ltd. is trading above its 100 day SMA of 5036.6
More from Alkem Laboratories Ltd.
Recommended